Entero Healthcare Solutions Limited, India’s fastest-growing healthcare distributor, has finalized its acquisition of Anand Chemiceutics Private Limited, a leading distributor of diagnostic and MedTech products.

 

The move positions Entero at the forefront of India’s rapidly expanding MedTech market, combining Anand Chemiceutics’ two decades of expertise, trusted partnerships, and pan-India network with Entero’s distribution scale and capabilities. 

 

Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions, offering specialized distribution, marketing, and service support for diagnostic equipment, reagents, and advanced genomics, along with turnkey solutions for hospitals and laboratories.

 

Commenting on the deal, Prabhat Agrawal, MD and CEO, Entero Healthcare, said: "I am pleased to welcome Anand Chemiceutics to Entero group. Its extensive track record, partnerships with global diagnostics players and expertise in MedTech combined with our distribution reach, capabilities and resources strategically positions us to build scale in this attractive segment."

 

Jayesh Sancheti, MD, Anand Chemiceutics, added: "This is more than a partnership — it’s the strategic integration of Anand Chemiceutics legacy trust in diagnostics and MedTech distribution with Entero's scale and technology, creating a powerhouse that creates meaningful difference in patients’ lifecycle."

 

The acquisition, first announced on 12 November 2025, is expected to boost Entero’s MedTech revenue to over INR 1,000 crore annually in the next financial year. The deal also strengthens opportunities for leveraging combined distribution strength, partnerships, geographical reach, and expertise, accelerating Entero’s vision of becoming a fully integrated healthcare supply chain solutions provider.